Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

5 results
Display

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Yagisawa K, Kobayashi T, Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida M, Saito E, Nakano M, Matsubara H, Hisamatsu T, Hibi T

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evolution of Diabetes Care in Hong Kong: From the Hong Kong Diabetes Register to JADE-PEARL Program to RAMP and PEP Program

Ng IH, Cheung KK, Yau TT, Chow E, Ozaki R, Chan JC

The rapid increase in diabetes prevalence globally has contributed to large increases in health care expenditure on diabetic complications, posing a major health burden to countries worldwide. Asians are commonly...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab

Okabayashi S, Kobayashi , Sujino T, Ozaki R, Umeda S, Toyonaga T, Saito E, Nakano M, Tablante M, Morinaga S, Hibi T

Extracolonic involvement of the gastrointestinal tract is extremely uncommon in ulcerative colitis (UC) and rarely found in the upper gastrointestinal tract or in postoperative cases since it typically responds to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis

Okabayashi S, Kobayashi , Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T

BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Yagisawa K, Kobayashi , Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida , Saito E, Nakano M, Matsubara , Hisamatsu , Hibi T

BACKGROUND/AIMS: Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr